- Home
- MMSI vs PTGX Comparison
MMSI vs PTGX Comparison
Compare MMSI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMSI
- PTGX
- Stock Information
- Founded
- MMSI 1987
- PTGX 2006
- Country
- MMSI United States
- PTGX United States
- Employees
- MMSI N/A
- PTGX N/A
- Industry
- MMSI Medical/Dental Instruments
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MMSI Health Care
- PTGX Health Care
- Exchange
- MMSI Nasdaq
- PTGX Nasdaq
- Market Cap
- MMSI 5.0B
- PTGX 4.0B
- IPO Year
- MMSI 1990
- PTGX 2016
- Fundamental
- Price
- MMSI $82.38
- PTGX $65.23
- Analyst Decision
- MMSI Strong Buy
- PTGX Strong Buy
- Analyst Count
- MMSI 8
- PTGX 8
- Target Price
- MMSI $107.50
- PTGX $71.13
- AVG Volume (30 Days)
- MMSI 740.8K
- PTGX 1.0M
- Earning Date
- MMSI 10-30-2025
- PTGX 11-06-2025
- Dividend Yield
- MMSI N/A
- PTGX N/A
- EPS Growth
- MMSI N/A
- PTGX N/A
- EPS
- MMSI 1.97
- PTGX 0.80
- Revenue
- MMSI $1,432,816,000.00
- PTGX $209,180,000.00
- Revenue This Year
- MMSI $12.79
- PTGX N/A
- Revenue Next Year
- MMSI $6.34
- PTGX $248.17
- P/E Ratio
- MMSI $42.24
- PTGX $81.41
- Revenue Growth
- MMSI 10.11
- PTGX N/A
- 52 Week Low
- MMSI $79.10
- PTGX $33.31
- 52 Week High
- MMSI $111.45
- PTGX $68.26
- Technical
- Relative Strength Index (RSI)
- MMSI 43.86
- PTGX 58.33
- Support Level
- MMSI $80.05
- PTGX $63.71
- Resistance Level
- MMSI $84.84
- PTGX $66.87
- Average True Range (ATR)
- MMSI 1.86
- PTGX 2.53
- MACD
- MMSI 0.17
- PTGX -0.19
- Stochastic Oscillator
- MMSI 62.13
- PTGX 63.47
About MMSI Merit Medical Systems Inc.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.